---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-24-000100"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:01:32.359853+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Instil Bio Q3 net loss $3.54/sh; cash $122.9M; licensed PD-L1xVEGF bispecific SYN-2510

## Summary
- Licensed SYN-2510 (PD-L1xVEGF bispecific) and SYN-27M (CTLA-4 antibody) from ImmuneOnco for global ex-China rights.
- Clinical data update for SYN-2510 monotherapy in China expected 1H 2025; Phase 1b/2 combo in NSCLC late 2024, TNBC 1H 2025 in China.
- U.S. study of SYN-2510 in NSCLC targeted to start 2H 2025.
- Cash, equivalents & securities $122.9M as of Sept 30, 2024 (down from $175.0M Dec 31, 2023); cash runway beyond 2026.
- Q3 2024 net loss $3.54 per share vs $10.37 in Q3 2023; non-GAAP loss $2.55 vs $2.53.

## SEC filing metadata
- accession: 0001789769-24-000100
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976924000100/0001789769-24-000100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976924000100/til-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-24-000100
- JSON: https://secwatch.observer/filing/0001789769-24-000100.json
- Plain text: https://secwatch.observer/filing/0001789769-24-000100.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.